NeOnc Q4 net loss $62.1M ($3.20/sh); NEO212 Phase 1 complete, NEO100 Phase 2a enrolled

NEONC TECHNOLOGIES HOLDINGS, INC.

Q4 net loss $62.1M ($3.20 diluted EPS) vs $11.9M ($0.69) in Q4 2024; G&A surged to $4.8M from $1.7M.
NEO212 Phase 1 complete; RP2D set at 610 mg; company plans Type B End-of-Phase 1 FDA meeting for potential registrational study.
NEO100 Phase 2a fully enrolled in IDH1-mutant high-grade glioma; interim data readout expected ~August 2026.
PIPE financing anchored by $10M commitment from Cinctive Capital Management.
Leadership additions: Amir Heshmatpour named CEO, David Choi appointed CAO; two neuro-oncologists joined SAB.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.